. 2022 Apr 24;13(4):276–286. doi: 10.5306/wjco.v13.i4.276

Table 4.

Clinical trials of mesenchymal-epithelial transition factor inhibitors

Drug	Clinical trial	Phase	Treatment	Objective	Status
Glesatinib	NCT02954991	2	Glesatinib + Nivolumab	ORR	Active, not recruiting
Multi-TKI	NCT02954991	2	Glesatinib + Nivolumab	ORR	Active, not recruiting
Glesatinib	NCT02544633	2	Glesatinib	ORR	Completed
Multi-TKI	NCT02544633	2	Glesatinib	ORR	Completed
Merestinib	NCT02920996	2	Merestinib	ORR	Active, not recruiting
Multi-TKI	NCT02920996	2	Merestinib	ORR	Active, not recruiting
Savolitinib	NCT02897479	2	Savolitinib	ORR	Active, not recruiting
Selective-TKI	NCT02897479	2	Savolitinib	ORR	Active, not recruiting
Telisotuzumab (ABBV 399)	NCT03574753	2	ABBV-399	ORR	Completed
MET-mab	NCT03574753	2	ABBV-399	ORR	Completed
JNJ-61186372	NCT02609776	1	JNJ-61186372	ORR, security	Recruiting
EGFR and MET mab	NCT02609776	1	JNJ-61186372	ORR, security	Recruiting

TKI: Tyrosine kinase inhibitor; mab: Monoclonal antibody; ORR: Overall response rate; MET: Mesenchymal-epithelial transition factor; EGFR: Epidermal growth factor receptor.